Baird analyst David Koning maintains WNS (Hldgs) (NYSE:WNS) with a Neutral and raises the price target from $88 to $90.
BTIG Maintains Buy on Freeline Therapeutics, Lowers Price Target to $5
BTIG analyst Yun Zhong maintains Freeline Therapeutics (NASDAQ:FRLN) with a Buy and lowers the price target from $10 to $5.